欧美日韩精品,成人欧美一区二区三区视频不卡 ,高H粗口调教羞辱SM文女王动画,久久国产精品夜色

設(shè)為首頁 加入收藏 中文版 English

The current position: Home>News

Jilin Zhongke Bio-engineering Co., Ltd. (JZB) founded in May 2007. JZB registered address is Changchun City, Jilin Province of P. R. China. Registered capital is 100 million RMB. JZB mainly engaged ... [more]
News

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines
NIH Director Francis S. Collins, M.D., Ph.D., today announced the approval of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.
"I am happy to say that we now have human embryonic stem cell lines eligible for use by our research community under our new stem cell policy," Dr. Collins said. "In accordance with the guidelines, these stem cell lines were derived from embryos that were donated under ethically sound informed consent processes. More lines are under review now, and we anticipate continuing to expand this list of responsibly derived lines eligible for NIH funding."
Children's Hospital Boston developed 11 of the approved lines and Rockefeller University in New York City developed two of the approved lines. An additional 96 lines have been submitted to NIH for either internal administrative review or consideration by the external Working Group for Human Embryonic Stem Cell Eligibility Review and the NIH Advisory Committee to the Director (ACD), including more than 20 that will be considered by the ACD on December 4, 2009. The working group provides findings to the ACD, which makes recommendations to the NIH Director, who decides whether the hESCs may be used in NIH-funded research and lists those deemed eligible on the NIH Human Embryonic Stem Cell Registry.
Research using hESCs is already yielding information about the complex events that occur during human development. Researchers hope that eventually cells differentiated from hESCs may be used to treat a myriad of diseases, conditions, and disabilities and to test the safety of new drugs in the laboratory

 

上一篇:Geron Enrolls First Patient In Clinical Trial Of GRNOPC1 - Quick Facts

下一篇:A New Milestone: US released the Phase II Stem Cell Clinical Trials

版權(quán)所有? 吉林省中科生物工程有限公司 吉ICP備12000258號
客服
live chat
<bdo id="zhlub"><rt id="zhlub"></rt></bdo>
      <rp id="zhlub"><center id="zhlub"><optgroup id="zhlub"></optgroup></center></rp>
      1. <menu id="zhlub"></menu>

        主站蜘蛛池模板: 辽中县| 巴林右旗| 十堰市| 南阳市| 霍城县| 曲阳县| 靖边县| 湘潭县| 鞍山市| 东山县| 永春县| 乌鲁木齐市| 枞阳县| 禄丰县| 元朗区| 依兰县| 禹城市| 滨海县| 寿宁县| 北宁市| 山西省| 荔波县| 舞钢市| 新巴尔虎右旗| 密山市| 唐海县| 镇安县| 浮山县| 册亨县| 斗六市| 九江县| 岳池县| 辽阳市| 桑植县| 莫力| 喜德县| 常德市| 赣榆县| 鹿泉市| 通海县| 郴州市|